Patients who adhere to a CancerIQ cancer prevention plan, or cancer survivorship plan, are more likely to catch a cancer before it grows beyond 1 centimeter, says Feyi Olopade Ayodele, MBA, chief executive officer at CancerIQ.
Patients who adhere to a CancerIQ cancer prevention plan, or cancer survivorship plan, are more likely to catch a cancer before it grows beyond 1 centimeter, says Feyi Olopade Ayodele, MBA, chief executive officer at CancerIQ.
Transcript
What are the success rates for predicting cancer risk by using genetic services?
At CancerIQ, we look at success in multiple different ways. We are not a diagnostic test ourselves. We really do rely on some of the highest quality genetic testing labs that are out there and we partner with them to make sure our providers can access best-in-class genetic testing. But when it comes to the benefits or repeatable outcomes that CancerIQ can drive, this really is our secret sauce. We’ve already found that patients that adhere to a CancerIQ cancer prevention plan, or cancer survivorship plan are more likely to catch a cancer before it grows beyond 1 centimeter.
To date, in the case study that we’re going to talk about [at the Association of Community Cancer Centers 45th Annual Meeting & Cancer Center Business Summit], you’ll see that we were able to find 3 patients who already had cancer using that breast MRI that CancerIQ recommended before it grew beyond a centimeter. They had a much higher chance of survival, less costly treatment, and we’ve demonstrated, full circle, CancerIQ’s impact on early detection.
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Dr Al Benson on Reimbursement for Supportive Care When Treating Patients With Cancer
March 22nd 2024Al Benson, MD, FACP, FACCC, FASCO, medical oncologist at Northwestern University Feinberg School of Medicine and associate director of the Robert E. Tillery Comprehensive Cancer Center, discussed findings from a national survey assessing barriers to comprehensive cancer care delivery.
Read More
FDA Approves Tislelizumab for Advanced or Metastatic ESCC After Chemotherapy
March 15th 2024The FDA has approved tislelizumab-jsgr (Tevimbra) for single-agent use in adult patients with unresectable or metastatic esophageal squamous cell carcinoma following prior systemic chemotherapy that did not include a PD-1/PD-L1 inhibitor.
Read More